- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02141828
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada
- The Hospital For Sick Kids
-
-
-
-
California
-
Los Angeles, California, United States, 90027
- Childrens Hospital Los Angeles
-
San Francisco, California, United States, 94143
- University of California San Francisco Medical Center-Parnassus
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Children's Hospital Colorado
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory Children's Healthcare of Atlanta
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Institute
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age: >3 months to <18 years of age.
Diagnosis: Patients must have documented relapsed/refractory ALL, AML, or acute leukemia of ambiguous lineage and meet the following criteria:
- Patients must have at least received an appropriate induction therapy regimen. Patients with persistent leukemia after induction therapy, or with recurrence of leukemia at any time during the course of treatment (including allogeneic HSCT) are eligible;
- Patients must have > 10% leukemic blasts in the bone marrow;
- Patients must have rearrangement involving the MLL gene, including reciprocal chromosomal translocations involving 11q23 by FISH, cytogenetic analysis, polymerase chain reaction (PCR) or next-generation sequencing (NGS) OR partial tandem duplication (PTD) of MLL by PCR or NGS.
- Therapeutic Options: Patients must be ineligible or inappropriate for other treatment regimens known to have curative potential.
- Performance Level: Karnofsky > 50% for pts > 12 years; Lansky > 50% for pts < 12 years of age.
Prior Therapy: Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.
Myelosuppressive Chemotherapy:
- 14 days must have elapsed since the completion of cytotoxic therapy
- Patients may receive hydroxyurea, low-dose cytarabine and/or glucocorticoids to control peripheral blood leukemic cell counts at study entry
- At least 7 days since the completion of therapy with hematopoietic growth factors
- At least 7 days since the completion of therapy with a biologic agent
- At least 21 days since receipt of chimeric antigen receptor therapy or other modified T cell therapy
- At least 60 days from prior total body irradiation (TBI)
- At least 60 days must have elapsed from hematopoietic stem cell transplantation (HSCT)
Renal and Hepatic Function: Patient must have adequate renal and hepatic functions as indicated by the following laboratory values:
- Patient must have a calculated creatinine clearance or radioisotope GFR > 60mL/min/1.73m2 or a normal serum creatinine based on age/gender
- Total bilirubin < 1.5 x ULN for age or normal conjugated bilirubin
- ALT and AST < 3 x ULN (unless attributed to leukemic involvement)
- Cardiac Function: Patient must have a shortening fraction (SF) of > 27% or an ejection fraction (EF) of > 50% by echocardiogram or MUGA scan.
Exclusion Criteria:
- Patients with CNS 3 disease or symptomatic CNS disease
- Clinically active heart disease including prolonged QTc or prolonged PR interval, or history of arrhythmias
- On immunosuppressive or other anti-leukemic therapy, excluding patients receiving glucocorticoids for management of circulating blast count or patients on a stable dose (<20mg/m2/day prednisone or equivalent) of systemic or topical glucocorticoid therapy with ≤ Grade 1 GvHD or tapering dose of calcineurin inhibitor
- Patients with known bleeding diathesis or prothrombin time (PT) or aPTT >1.5 x ULN or fibrinogen <0.5 x LLN
- Receiving prophylactic use of hematopoietic colony stimulating factors
- Known history of infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus (HBsAg positive) or hepatitis C virus (anti-HCV positive)
- Being actively treated for another concurrent malignancy
- Pregnant or nursing females;
- Male patients not willing to use a condom
- Uncontrolled intercurrent illness including, but not limited to uncontrolled infection, significant graft-versus-host-disease (GvHD) (Grade 2-4), or psychiatric illness/social situations that would limit compliance with study requirements
- Patients who are concurrently receiving strong inducers/inhibitors of CYP3A
- Patients with known history of Trisomy 21 (Down Syndrome), history of congenital immunodeficiency or inherited marrow failure disorder.
- Patients with known bleeding diathesis, or PT (Prothrombin time) or aPTT (activated partial thromboplastin time) > 1.5x ULN or <0.5x LLN.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: EPZ-5676
EPZ-5676 Dose escalation and expansion cohorts
|
28-day continuous IV infusion of each 28-day cycle, given until disease progression or unacceptable toxicity develops.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of EPZ-5676.
Time Frame: 12 months
|
To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of EPZ-5676 as determined by incidence of protocol-specified dose-limiting adverse events.
|
12 months
|
To assess the safety and tolerability of EPZ-5676 administered as a continuous intravenous (CIV) infusion
Time Frame: 22 months
|
Safety and tolerability will be assessed by the incidence of adverse events in patients treated with EPZ-5676 and the evaluation of adverse events, vital signs, physical examination, 12-lead ECG, and laboratory assessments.
|
22 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine the pharmacokinetic (PK) and pharmacodynamic (PD) profile of EPZ-5676
Time Frame: 18 months
|
The pharmacokinetic (PK) profile will include the analysis of Cmax, AUC and steady state concentration of EPZ-5676. The pharmacodynamic (PD) profile will assess the effects of EPZ-5676 in peripheral blood mononuclear (PBMC) and bone marrow cells. |
18 months
|
Evaluate early evidence of anti-tumor activity
Time Frame: 18 months
|
Anti-tumor activity will be assessed by objective response (OR) in pediatric patients
|
18 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine cerebrospinal fluid (CSF) concentrations EPZ-5676 in pediatric patients receiving EPZ-5676 by CIV infusion
Time Frame: 18 months
|
18 months
|
|
Analysis of tumor cells for somatic mutations as potential predictors of response
Time Frame: 18 months
|
Somatic mutations to include mRNA and proteins or markers of biological pathways as potential predictors of response to EPZ-5676 treatment
|
18 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Neal Shukla, MD, Memorial Sloan Kettering Cancer Center
- Principal Investigator: Lia Gore, MD, Children's Hospital Colorado
- Principal Investigator: Pat Brown, MD, Johns Hopkins University
- Principal Investigator: Lewis Silverman, MD, Dana Farber
- Principal Investigator: Jim A Whitlock, MD, Hospital of Sick Kids
- Principal Investigator: Cynthia Wetmore, MD PhD, Emory Children's Healthcare of Atlanta
- Principal Investigator: Todd Cooper, MD, Seattle Children's Hospital
- Principal Investigator: Maureen O'Brien, MD, Children's Hospital Medical Center, Cincinnati
- Principal Investigator: Mignon Loh, MD, University of California, San Francisco
- Principal Investigator: Paul Gaynon, MD, Children's Hospital Los Angeles
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EPZ-5676-12-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
Clinical Trials on EPZ-5676
-
Epizyme, Inc.CelgeneCompletedAcute Myeloid Leukemia | Myeloproliferative Disorders | Acute Lymphoblastic Leukemia | Myelodysplastic SyndromeUnited States, Germany, Netherlands
-
National Cancer Institute (NCI)CompletedRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Leukemia Cutis | Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLLUnited States
-
National Cancer Institute (NCI)Children's Oncology GroupActive, not recruitingRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Ann Arbor Stage III Hodgkin Lymphoma | Ann Arbor Stage IV Hodgkin Lymphoma | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent... and other conditionsUnited States, Puerto Rico
-
Epizyme, Inc.CompletedSynovial Sarcoma | INI1-negative Tumors | Malignant Rhabdoid Tumor of Ovary | Rhabdoid TumorsUnited States, France, Canada, Italy, Germany, United Kingdom, Australia, Denmark, Netherlands
-
Epizyme, Inc.No longer availableRenal Cell Carcinoma | Malignant Mesothelioma | Chondrosarcoma | Synovial Sarcoma | Renal Medullary Carcinoma | Malignant Rhabdoid Tumor | Poorly Differentiated Chordoma | Malignant Rhabdoid Tumor of Ovary | Epithelioid Malignant Peripheral Nerve Sheath Tumor | Sinonasal Carcinoma | Spindle Cell Sarcoma | Epithelioid... and other conditions
-
Epizyme, Inc.Sponsor GmbHRecruitingHepatic Impairment | Advanced Malignant Solid TumorFrance, Belgium, United States, Poland, Slovakia
-
Epizyme, Inc.Active, not recruitingSynovial Sarcoma | Epithelioid Sarcoma | Renal Medullary Carcinoma | Malignant Rhabdoid Tumors (MRT) | Rhabdoid Tumors of the Kidney (RTK) | Atypical Teratoid Rhabdoid Tumors (ATRT) | Selected Tumors With Rhabdoid Features | INI1-negative Tumors | Malignant Rhabdoid Tumor of Ovary | Poorly Differentiated... and other conditionsFrance, United States, Australia, Taiwan, Belgium, United Kingdom, Canada, Germany, Italy
-
Epizyme, Inc.Enrolling by invitationAdvanced Solid Tumors | Mesothelioma | Synovial Sarcoma | Renal Medullary Carcinoma | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Non-Hodgkin Lymphoma (NHL) | Epitheliod Sarcoma (ES)United States, France, United Kingdom, Poland, Australia, Belgium, Ukraine
-
Epizyme, Inc.CompletedMesothelioma | BAP1 Loss of FunctionUnited States, United Kingdom, France
-
Epizyme, Inc.CompletedFollicular Lymphoma | Marginal Zone Lymphoma | Advanced Solid Tumors | Mantle-Cell Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal LymphomaUnited Kingdom